ZIVO Bioscience (ZIVO) Competitors

ZIVO Bioscience logo
$5.50 0.00 (0.00%)
As of 11/20/2026 11:14 AM Eastern

ZIVO vs. BGM, NRXP, VANI, PLYX, and CPIX

Should you buy ZIVO Bioscience stock or one of its competitors? ZIVO Bioscience's main competitors and comparable companies include BGM Group (BGM), NRx Pharmaceuticals (NRXP), Vivani Medical (VANI), Polaryx Therapeutics (PLYX), and Cumberland Pharmaceuticals (CPIX). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "pharmaceuticals" industry.

How does ZIVO Bioscience compare to BGM Group?

ZIVO Bioscience (NASDAQ:ZIVO) and BGM Group (NASDAQ:BGM) are both small-cap healthcare companies, but which is the superior stock? We will contrast the two businesses based on the strength of their institutional ownership, earnings, profitability, risk, analyst recommendations, valuation, dividends and media sentiment.

In the previous week, BGM Group had 3 more articles in the media than ZIVO Bioscience. MarketBeat recorded 3 mentions for BGM Group and 0 mentions for ZIVO Bioscience. BGM Group's average media sentiment score of 0.43 beat ZIVO Bioscience's score of 0.00 indicating that BGM Group is being referred to more favorably in the news media.

Company Overall Sentiment
ZIVO Bioscience Neutral
BGM Group Neutral

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
ZIVO Bioscience
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00
BGM Group
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00

12.8% of ZIVO Bioscience shares are held by institutional investors. 48.9% of ZIVO Bioscience shares are held by insiders. Comparatively, 58.7% of BGM Group shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

ZIVO Bioscience has a beta of 0.3, suggesting that its share price is 70% less volatile than the broader market. Comparatively, BGM Group has a beta of 1.88, suggesting that its share price is 88% more volatile than the broader market.

Company Net Margins Return on Equity Return on Assets
ZIVO BioscienceN/A N/A -2,240.92%
BGM Group N/A N/A N/A

ZIVO Bioscience has higher earnings, but lower revenue than BGM Group.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
ZIVO Bioscience$15.85K1,462.62-$7.78M-$1.19N/A
BGM Group$47.90M2.07-$19.94MN/AN/A

Summary

BGM Group beats ZIVO Bioscience on 7 of the 10 factors compared between the two stocks.

How does ZIVO Bioscience compare to NRx Pharmaceuticals?

NRx Pharmaceuticals (NASDAQ:NRXP) and ZIVO Bioscience (NASDAQ:ZIVO) are both small-cap healthcare companies, but which is the better business? We will contrast the two companies based on the strength of their media sentiment, risk, profitability, earnings, dividends, analyst recommendations, valuation and institutional ownership.

4.3% of NRx Pharmaceuticals shares are owned by institutional investors. Comparatively, 12.8% of ZIVO Bioscience shares are owned by institutional investors. 4.9% of NRx Pharmaceuticals shares are owned by insiders. Comparatively, 48.9% of ZIVO Bioscience shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

ZIVO Bioscience has lower revenue, but higher earnings than NRx Pharmaceuticals. NRx Pharmaceuticals is trading at a lower price-to-earnings ratio than ZIVO Bioscience, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
NRx Pharmaceuticals$3.39M27.65-$28.62M-$0.34N/A
ZIVO Bioscience$15.85K1,462.62-$7.78M-$1.19N/A

In the previous week, NRx Pharmaceuticals had 15 more articles in the media than ZIVO Bioscience. MarketBeat recorded 15 mentions for NRx Pharmaceuticals and 0 mentions for ZIVO Bioscience. NRx Pharmaceuticals' average media sentiment score of 0.46 beat ZIVO Bioscience's score of 0.00 indicating that NRx Pharmaceuticals is being referred to more favorably in the media.

Company Overall Sentiment
NRx Pharmaceuticals Neutral
ZIVO Bioscience Neutral

NRx Pharmaceuticals has a beta of 2.11, suggesting that its stock price is 111% more volatile than the broader market. Comparatively, ZIVO Bioscience has a beta of 0.3, suggesting that its stock price is 70% less volatile than the broader market.

ZIVO Bioscience has a net margin of 0.00% compared to NRx Pharmaceuticals' net margin of -458.48%.

Company Net Margins Return on Equity Return on Assets
NRx Pharmaceuticals-458.48% N/A -45.98%
ZIVO Bioscience N/A N/A -2,240.92%

NRx Pharmaceuticals currently has a consensus price target of $35.00, indicating a potential upside of 1,527.91%. Given NRx Pharmaceuticals' stronger consensus rating and higher probable upside, equities research analysts clearly believe NRx Pharmaceuticals is more favorable than ZIVO Bioscience.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
NRx Pharmaceuticals
1 Sell rating(s)
1 Hold rating(s)
6 Buy rating(s)
0 Strong Buy rating(s)
2.63
ZIVO Bioscience
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00

Summary

NRx Pharmaceuticals beats ZIVO Bioscience on 9 of the 15 factors compared between the two stocks.

How does ZIVO Bioscience compare to Vivani Medical?

ZIVO Bioscience (NASDAQ:ZIVO) and Vivani Medical (NASDAQ:VANI) are both small-cap healthcare companies, but which is the superior stock? We will compare the two companies based on the strength of their analyst recommendations, profitability, risk, valuation, institutional ownership, dividends, media sentiment and earnings.

ZIVO Bioscience has higher revenue and earnings than Vivani Medical. ZIVO Bioscience is trading at a lower price-to-earnings ratio than Vivani Medical, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
ZIVO Bioscience$15.85K1,462.62-$7.78M-$1.19N/A
Vivani MedicalN/AN/A-$26.61M-$0.32N/A

ZIVO Bioscience has a beta of 0.3, suggesting that its stock price is 70% less volatile than the broader market. Comparatively, Vivani Medical has a beta of 2.51, suggesting that its stock price is 151% more volatile than the broader market.

In the previous week, Vivani Medical had 15 more articles in the media than ZIVO Bioscience. MarketBeat recorded 15 mentions for Vivani Medical and 0 mentions for ZIVO Bioscience. Vivani Medical's average media sentiment score of 1.25 beat ZIVO Bioscience's score of 0.00 indicating that Vivani Medical is being referred to more favorably in the news media.

Company Overall Sentiment
ZIVO Bioscience Neutral
Vivani Medical Positive

12.8% of ZIVO Bioscience shares are owned by institutional investors. Comparatively, 6.8% of Vivani Medical shares are owned by institutional investors. 48.9% of ZIVO Bioscience shares are owned by insiders. Comparatively, 53.3% of Vivani Medical shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Vivani Medical has a consensus price target of $3.75, suggesting a potential upside of 228.95%. Given Vivani Medical's stronger consensus rating and higher probable upside, analysts plainly believe Vivani Medical is more favorable than ZIVO Bioscience.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
ZIVO Bioscience
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00
Vivani Medical
1 Sell rating(s)
0 Hold rating(s)
2 Buy rating(s)
0 Strong Buy rating(s)
2.33

ZIVO Bioscience's return on equity of 0.00% beat Vivani Medical's return on equity.

Company Net Margins Return on Equity Return on Assets
ZIVO BioscienceN/A N/A -2,240.92%
Vivani Medical N/A -161.39%-68.14%

Summary

Vivani Medical beats ZIVO Bioscience on 9 of the 14 factors compared between the two stocks.

How does ZIVO Bioscience compare to Polaryx Therapeutics?

Polaryx Therapeutics (NASDAQ:PLYX) and ZIVO Bioscience (NASDAQ:ZIVO) are both small-cap healthcare companies, but which is the better stock? We will contrast the two businesses based on the strength of their institutional ownership, valuation, media sentiment, analyst recommendations, profitability, risk, dividends and earnings.

In the previous week, Polaryx Therapeutics had 4 more articles in the media than ZIVO Bioscience. MarketBeat recorded 4 mentions for Polaryx Therapeutics and 0 mentions for ZIVO Bioscience. Polaryx Therapeutics' average media sentiment score of 0.23 beat ZIVO Bioscience's score of 0.00 indicating that Polaryx Therapeutics is being referred to more favorably in the media.

Company Overall Sentiment
Polaryx Therapeutics Neutral
ZIVO Bioscience Neutral

12.8% of ZIVO Bioscience shares are owned by institutional investors. 45.8% of Polaryx Therapeutics shares are owned by company insiders. Comparatively, 48.9% of ZIVO Bioscience shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

ZIVO Bioscience's return on equity of 0.00% beat Polaryx Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Polaryx TherapeuticsN/A -136.66% -120.26%
ZIVO Bioscience N/A N/A -2,240.92%

Polaryx Therapeutics presently has a consensus price target of $7.67, indicating a potential upside of 476.44%. Given Polaryx Therapeutics' stronger consensus rating and higher probable upside, research analysts clearly believe Polaryx Therapeutics is more favorable than ZIVO Bioscience.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Polaryx Therapeutics
1 Sell rating(s)
1 Hold rating(s)
2 Buy rating(s)
1 Strong Buy rating(s)
2.60
ZIVO Bioscience
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00

ZIVO Bioscience has higher revenue and earnings than Polaryx Therapeutics. Polaryx Therapeutics is trading at a lower price-to-earnings ratio than ZIVO Bioscience, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Polaryx TherapeuticsN/AN/A-$8.98M-$0.15N/A
ZIVO Bioscience$15.85K1,462.62-$7.78M-$1.19N/A

Summary

Polaryx Therapeutics beats ZIVO Bioscience on 8 of the 14 factors compared between the two stocks.

How does ZIVO Bioscience compare to Cumberland Pharmaceuticals?

ZIVO Bioscience (NASDAQ:ZIVO) and Cumberland Pharmaceuticals (NASDAQ:CPIX) are both small-cap healthcare companies, but which is the superior investment? We will contrast the two businesses based on the strength of their earnings, media sentiment, risk, valuation, institutional ownership, profitability, dividends and analyst recommendations.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
ZIVO Bioscience
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00
Cumberland Pharmaceuticals
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00

In the previous week, Cumberland Pharmaceuticals had 2 more articles in the media than ZIVO Bioscience. MarketBeat recorded 2 mentions for Cumberland Pharmaceuticals and 0 mentions for ZIVO Bioscience. ZIVO Bioscience's average media sentiment score of 0.00 equaled Cumberland Pharmaceuticals'average media sentiment score.

Company Overall Sentiment
ZIVO Bioscience Neutral
Cumberland Pharmaceuticals Neutral

ZIVO Bioscience has a beta of 0.3, indicating that its share price is 70% less volatile than the broader market. Comparatively, Cumberland Pharmaceuticals has a beta of 0.16, indicating that its share price is 84% less volatile than the broader market.

Cumberland Pharmaceuticals has higher revenue and earnings than ZIVO Bioscience. ZIVO Bioscience is trading at a lower price-to-earnings ratio than Cumberland Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
ZIVO Bioscience$15.85K1,462.62-$7.78M-$1.19N/A
Cumberland Pharmaceuticals$44.52M1.97-$2.84M$4.491.30

Cumberland Pharmaceuticals has a net margin of 274.38% compared to ZIVO Bioscience's net margin of 0.00%. ZIVO Bioscience's return on equity of 0.00% beat Cumberland Pharmaceuticals' return on equity.

Company Net Margins Return on Equity Return on Assets
ZIVO BioscienceN/A N/A -2,240.92%
Cumberland Pharmaceuticals 274.38%-19.50%-8.12%

12.8% of ZIVO Bioscience shares are held by institutional investors. Comparatively, 15.5% of Cumberland Pharmaceuticals shares are held by institutional investors. 48.9% of ZIVO Bioscience shares are held by company insiders. Comparatively, 42.1% of Cumberland Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Summary

Cumberland Pharmaceuticals beats ZIVO Bioscience on 9 of the 13 factors compared between the two stocks.

Get ZIVO Bioscience News Delivered to You Automatically

Sign up to receive the latest news and ratings for ZIVO and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ZIVO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

ZIVO vs. The Competition

MetricZIVO BiosciencePharmaceuticals IndustryHealthcare SectorNASDAQ Exchange
Market Cap$23.18M$13.12B$7.44B$10.86B
Dividend YieldN/A2.62%2.51%4.58%
P/E Ratio-1.1327.8232.5628.63
Price / Sales1,462.627.297.745.15
Price / CashN/A15.2220.2520.77
Price / Book-6.795.164.343.51
Net Income-$7.78M$2.86B$3.51B$394.12M
7 Day Performance-4.51%-7.27%-8.07%-8.97%
1 Month Performance-11.72%-9.60%-10.29%-11.61%
1 Year Performance-31.25%-9.28%-4.70%-11.21%

ZIVO Bioscience Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
ZIVO
ZIVO Bioscience
N/A$5.50
flat
N/A-31.3%$23.18M$15.85KN/A7
BGM
BGM Group
0.9978 of 5 stars
$7.57
-1.6%
N/A-96.8%$96.11M$37.92MN/A298
NRXP
NRx Pharmaceuticals
2.4712 of 5 stars
$2.19
-3.9%
$35.00
+1,498.2%
+0.9%$95.59M$1.23MN/A29
VANI
Vivani Medical
3.9094 of 5 stars
$1.01
+2.7%
$3.75
+271.3%
-13.6%$91.10MN/AN/A36
PLYX
Polaryx Therapeutics
1.6999 of 5 stars
$1.77
-5.9%
$7.67
+333.1%
N/A$88.23MN/AN/A11

Related Companies and Tools


This page (NASDAQ:ZIVO) was last updated on 11/22/2026 by MarketBeat.com Staff.
From Our Partners